[go: up one dir, main page]

AR063259A1 - Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua - Google Patents

Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua

Info

Publication number
AR063259A1
AR063259A1 ARP070104515A ARP070104515A AR063259A1 AR 063259 A1 AR063259 A1 AR 063259A1 AR P070104515 A ARP070104515 A AR P070104515A AR P070104515 A ARP070104515 A AR P070104515A AR 063259 A1 AR063259 A1 AR 063259A1
Authority
AR
Argentina
Prior art keywords
therapeutically effective
dosage form
ionic polymer
microincluded
pharmaceutical dosage
Prior art date
Application number
ARP070104515A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR063259A1 publication Critical patent/AR063259A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formas solidas de dosificacion farmacéutica para su administracion oral que comprende una cantidad terapéuticamente efectiva de una forma cristalina inestable o una forma amorfa de un compuesto terapéuticamente efectivo microincluido en un polímero ionico insoluble en agua. Los compuestos terapéuticamente efectivos, que tienen tendencia a melificar, son microincluidos en una matriz de polímero ionico insoluble en agua para proporcionar una forma de dosificacion con un perfil de disolucion rápido, reproducible y completo. Estas nuevas formas solidas de dosificacion farmacéutica son utiles para el tratamiento o control de tina serie de enfermedades. Reivindicacion 2: La forma de dosificacion de acuerdo con la reivindicacion 1, en la que el compuesto terapéuticamente efectivo es un compuesto activador de la glucoquinasa. Reivindicacion 4: La forma de dosificacion de acuerdo con la reivindicacion 3, en la que el compuesto activador de la glucoquinasa es 2(R)-(3-cloro-4- metanosulfonil-fenil)-3-ciclo-pentil-N-(5-(1(S),2-dihidroxietil)-pirazin-2-il]-propionamida. Reivindicacion 11: La forma de dosificacion de acuerdo con la reivindicacion 10, en la que el polímero ionico insoluble en agua es un copolímero de ácido metacrílico y etilacrilato. Reivindicacion 15: La forma de dosificacion de acuerdo con las reivindicaciones de 1 a 13 para el tratamiento de la diabetes tipo 2. Reivindicacion 16: Un método para la preparacion de una forma solida de dosificacion farmacéutica para su administracion oral que comprende la microinclusion de una cantidad terapéuticamente efectiva de una forma cristalina inestable o una forma amorfa en un polímero ionico insoluble en agua, en la que la proporcion del compuesto terapéuticamente efectivo y el portador de polímero ionico es de 5:1 a 1:5, respectivamente.
ARP070104515A 2006-10-13 2007-10-11 Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua AR063259A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85185206P 2006-10-13 2006-10-13
US95440107P 2007-08-07 2007-08-07

Publications (1)

Publication Number Publication Date
AR063259A1 true AR063259A1 (es) 2009-01-14

Family

ID=38857877

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104515A AR063259A1 (es) 2006-10-13 2007-10-11 Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua

Country Status (16)

Country Link
US (1) US20080107725A1 (es)
EP (1) EP2079447A1 (es)
JP (1) JP2010505901A (es)
KR (1) KR20090053858A (es)
AR (1) AR063259A1 (es)
AU (1) AU2007306402A1 (es)
BR (1) BRPI0719880A2 (es)
CA (1) CA2665604A1 (es)
CL (1) CL2007002921A1 (es)
IL (1) IL197871A0 (es)
MX (1) MX2009003516A (es)
NO (1) NO20091274L (es)
PE (1) PE20081461A1 (es)
RU (1) RU2009117711A (es)
TW (1) TW200824709A (es)
WO (1) WO2008043701A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2863409A1 (en) * 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
EP3228307A1 (en) * 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CA3046861A1 (en) * 2016-12-15 2018-06-21 Hua Medicine (Shanghai) Ltd. Oral preparation of glucokinase activator and preparation method therefor
CN114246950A (zh) * 2018-05-31 2022-03-29 华领医药技术（上海）有限公司 含葡萄糖激酶激活剂和α-葡萄糖苷酶抑制剂的药物组合及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
AU5609998A (en) * 1997-01-10 1998-08-03 Abbott Laboratories Tablet for the controlled release of active agents
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2248309T3 (es) * 2000-05-03 2006-03-16 F. Hoffmann-La Roche Ag Activadores de glucoquinasa conteniendo hidantoina.
EP1286663B1 (en) * 2000-05-18 2006-01-18 Therics, Inc. Encapsulating a toxic core within a non-toxic region in an oral dosage form
EP2305648A1 (en) * 2001-12-21 2011-04-06 Novo Nordisk A/S Amide derivatives useful as glucokinase activators
DE60328671D1 (de) * 2002-03-26 2009-09-17 Banyu Pharma Co Ltd Neue aminobenzamidderivate
WO2003090717A1 (en) * 2002-04-23 2003-11-06 Nanotherapeutics, Inc Process of forming and modifying particles and compositions produced thereby
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
AU2004275594A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes

Also Published As

Publication number Publication date
PE20081461A1 (es) 2008-10-18
TW200824709A (en) 2008-06-16
AU2007306402A1 (en) 2008-04-17
US20080107725A1 (en) 2008-05-08
BRPI0719880A2 (pt) 2014-06-10
IL197871A0 (en) 2009-12-24
NO20091274L (no) 2009-05-28
WO2008043701A1 (en) 2008-04-17
JP2010505901A (ja) 2010-02-25
KR20090053858A (ko) 2009-05-27
EP2079447A1 (en) 2009-07-22
CA2665604A1 (en) 2008-04-17
MX2009003516A (es) 2009-04-14
RU2009117711A (ru) 2010-11-20
CL2007002921A1 (es) 2008-05-30

Similar Documents

Publication Publication Date Title
AR063259A1 (es) Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
BRPI0414254A (pt) composição farmacêutica, e, métodos para fabricar uma composição farmacêutica, para o tratamento de pelo menos uma doença e para controlar a taxa de dissolução de uma formulação
AR111679A2 (es) Formulación farmacéutica de liberación controlada, procesos, usos, método
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
BRPI0412211A (pt) composições de liberação controlada
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
MX2009004856A (es) Matriz polimerica insoluble en agua para suministro de farmaco.
BRPI0507683A (pt) dose unitária com liberação de formulação farmacêutica com liberação controlada, processo para sua preparação, bem como uso de um copolìmero de poli(acrilato de etila, metacrilato de metila) neutro
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
EA201190300A1 (ru) Микроэлектрод и множественные микроэлектроды, содержащие устройства для высвобождения лекарственных средств в ткани
BR112017026746A2 (pt) composições de liberação de fármacos implantáveis e métodos de uso dos mesmos
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
AR052225A1 (es) Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
DE60219314D1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
PE20081464A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
RU2016114098A (ru) Новое производное аналога инсулина
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
ECSP17081071A (es) Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
RU2014126879A (ru) Композиции акампросата, способы их применения и содержащие их комбинации
AR048342A1 (es) FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal